Recently, the randomized, phase 3 SOLAR-1 trial showed that the treatment with alpelisib, a PI3Kα-specific inhibitor, in combination with fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, ER-positive/HER2-negative advanced breast cancer [46]. Here, PIK3CA is linked to breast cancer.